Literature DB >> 31206217

Transient Cold Storage Prior to Normothermic Liver Perfusion May Facilitate Adoption of a Novel Technology.

Carlo D L Ceresa1, David Nasralla1, Christopher J E Watson2, Andrew J Butler2, Constantin C Coussios3, Keziah Crick2, Leanne Hodson4, Charles Imber5, Wayel Jassem6, Simon R Knight1, Hynek Mergental7, Rutger J Ploeg1, Joerg M Pollok5, Alberto Quaglia6, A M James Shapiro8, Annemarie Weissenbacher1, Peter J Friend1.   

Abstract

Clinical adoption of normothermic machine perfusion (NMP) may be facilitated by simplifying logistics and reducing costs. This can be achieved by cold storage of livers for transportation to recipient centers before commencing NMP. The purpose of this study was to assess the safety and feasibility of post-static cold storage normothermic machine perfusion (pSCS-NMP) in liver transplantation. In this multicenter prospective study, 31 livers were transplanted. The primary endpoint was 30-day graft survival. Secondary endpoints included the following: peak posttransplant aspartate aminotransferase (AST), early allograft dysfunction (EAD), postreperfusion syndrome (PRS), adverse events, critical care and hospital stay, biliary complications, and 12-month graft survival. The 30-day graft survival rate was 94%. Livers were preserved for a total of 14 hours 10 minutes ± 4 hours 46 minutes, which included 6 hours 1 minute ± 1 hour 19 minutes of static cold storage before 8 hours 24 minutes ± 4 hours 4 minutes of NMP. Median peak serum AST in the first 7 days postoperatively was 457 U/L (92-8669 U/L), and 4 (13%) patients developed EAD. PRS was observed in 3 (10%) livers. The median duration of initial critical care stay was 3 days (1-20 days), and median hospital stay was 13 days (7-31 days). There were 7 (23%) patients who developed complications of grade 3b severity or above, and 2 (6%) patients developed biliary complications: 1 bile leak and 1 anastomotic stricture with no cases of ischemic cholangiopathy. The 12-month overall graft survival rate (including death with a functioning graft) was 84%. In conclusion, this study demonstrates that pSCS-NMP was feasible and safe, which may facilitate clinical adoption.
Copyright © 2019 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2019        PMID: 31206217     DOI: 10.1002/lt.25584

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  12 in total

Review 1.  Machine perfusion of the liver: applications in transplantation and beyond.

Authors:  Carlo D L Ceresa; David Nasralla; Joerg-Matthias Pollok; Peter J Friend
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-01-07       Impact factor: 46.802

2.  Heterogeneous indications and the need for viability assessment: An international survey on the use of machine perfusion in liver transplantation.

Authors:  Damiano Patrono; Davide Cussa; Federica Rigo; Renato Romagnoli
Journal:  Artif Organs       Date:  2021-09-08       Impact factor: 2.663

Review 3.  Hospital-Based Health Technology Assessment of Machine Perfusion Systems for Human Liver Transplantation.

Authors:  Paolo De Simone; Davide Ghinolfi
Journal:  Transpl Int       Date:  2022-05-27       Impact factor: 3.842

4.  Viability testing of discarded livers with normothermic machine perfusion: Alleviating the organ shortage outweighs the cost.

Authors:  Siavash Raigani; Reinier J De Vries; Cailah Carroll; Ya-Wen Chen; David C Chang; Stuti G Shroff; Korkut Uygun; Heidi Yeh
Journal:  Clin Transplant       Date:  2020-09-23       Impact factor: 2.863

Review 5.  Normothermic Machine Perfusion (NMP) of the Liver as a Platform for Therapeutic Interventions during Ex-Vivo Liver Preservation: A Review.

Authors:  Fungai Dengu; Syed Hussain Abbas; Georg Ebeling; David Nasralla
Journal:  J Clin Med       Date:  2020-04-07       Impact factor: 4.241

Review 6.  Transplanting Marginal Organs in the Era of Modern Machine Perfusion and Advanced Organ Monitoring.

Authors:  Thomas Resch; Benno Cardini; Rupert Oberhuber; Annemarie Weissenbacher; Julia Dumfarth; Christoph Krapf; Claudia Boesmueller; Dietmar Oefner; Michael Grimm; Sefan Schneeberger
Journal:  Front Immunol       Date:  2020-05-12       Impact factor: 7.561

Review 7.  Machine Perfusion of the Liver: A Review of Clinical Trials.

Authors:  Nikolaos Serifis; Rudy Matheson; Daniel Cloonan; Charles G Rickert; James F Markmann; Taylor M Coe
Journal:  Front Surg       Date:  2021-03-26

Review 8.  Viability Assessment in Liver Transplantation-What Is the Impact of Dynamic Organ Preservation?

Authors:  Rebecca Panconesi; Mauricio Flores Carvalho; Matteo Mueller; David Meierhofer; Philipp Dutkowski; Paolo Muiesan; Andrea Schlegel
Journal:  Biomedicines       Date:  2021-02-07

Review 9.  Preventing Tumour Recurrence after Liver Transplantation: The Role of Machine Perfusion.

Authors:  Yuri Boteon; Mauricio Alfredo Flores Carvalho; Rebecca Panconesi; Paolo Muiesan; Andrea Schlegel
Journal:  Int J Mol Sci       Date:  2020-08-12       Impact factor: 5.923

10.  Ex vivo machine perfusion: current applications and future directions in liver transplantation.

Authors:  Julian Michelotto; Joseph M G V Gassner; Simon Moosburner; Vanessa Muth; Madhukar S Patel; Markus Selzner; Johann Pratschke; Igor M Sauer; Nathanael Raschzok
Journal:  Langenbecks Arch Surg       Date:  2020-11-20       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.